Literature DB >> 17872495

HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.

Maria E Ramos-Nino1, Steven R Blumen, Tara Sabo-Attwood, Harvey Pass, Michele Carbone, Joseph R Testa, Deborah A Altomare, Brooke T Mossman.   

Abstract

The ligand hepatocyte growth factor/scatter factor (HGF) and its receptor tyrosine kinase, c-Met, are highly expressed in most human malignant mesotheliomas (MMs) and may contribute to their increased growth and viability. Based upon our observation that RNA silencing of fos-related antigen 1 (Fra-1) inhibited c-met expression in rat mesotheliomas (1), we hypothesized that Fra-1 was a key player in HGF-induced proliferation in human MMs. In three of seven human MM lines evaluated, HGF increased Fra-1 levels and phosphorylation of both extracellular signal-regulated kinase 5 (ERK5) and AKT that were inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor, LY290042. HGF-dependent phosphorylation and Fra-1 expression were decreased after knockdown of Fra-1, whereas overexpression of Fra-1 blocked the expression of mitogen/extracellular signal-regulated kinase kinases (MEK)5 at the mRNA and protein levels. Stable MM cell lines using a dnMEK5 showed that basal Fra-1 levels were increased in comparison to empty vector control lines. HGF also caused increased MM cell viability and proliferating cell nuclear antigen (PCNA) expression that were abolished by knockdown of MEK5 or Fra-1. Data suggest that HGF-induced effects in some MM cells are mediated via activation of a novel PI3K/ERK5/Fra-1 feedback pathway that might explain tumor-specific effects of c-Met inhibitors on MM and other tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872495      PMCID: PMC2214675          DOI: 10.1165/rcmb.2007-0206OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  40 in total

1.  Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells.

Authors:  D A Zajchowski; M F Bartholdi; Y Gong; L Webster; H L Liu; A Munishkin; C Beauheim; S Harvey; S P Ethier; P H Johnson
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  Inhibition of the met receptor in mesothelioma.

Authors:  Toru Mukohara; Gabriel Civiello; Ian J Davis; Michele L Taffaro; James Christensen; David E Fisher; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

3.  Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.

Authors:  M A Dickson; W C Hahn; Y Ino; V Ronfard; J Y Wu; R A Weinberg; D N Louis; F P Li; J G Rheinwald
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

4.  FRA-1 expression in hyperplastic and neoplastic thyroid diseases.

Authors:  G Chiappetta; G Tallini; M C De Biasio; F Pentimalli; F de Nigris; S Losito; M Fedele; S Battista; P Verde; M Santoro; A Fusco
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

5.  SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma.

Authors:  P Cacciotti; R Libener; P Betta; F Martini; C Porta; A Procopio; L Strizzi; L Penengo; M Tognon; L Mutti; G Gaudino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 6.  The Fos family of transcription factors and their role in tumourigenesis.

Authors:  Karin Milde-Langosch
Journal:  Eur J Cancer       Date:  2005-09-30       Impact factor: 9.162

7.  Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas.

Authors:  I Thirkettle; P Harvey; P S Hasleton; R Y Ball; R M Warn
Journal:  Histopathology       Date:  2000-06       Impact factor: 5.087

8.  Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC.

Authors:  Y C Hu; K Y Lam; S Law; J Wong; G Srivastava
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

9.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.

Authors:  G H Xiao; M Jeffers; A Bellacosa; Y Mitsuuchi; G F Vande Woude ; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

10.  Fra-1 expression in malignant and benign thyroid tumor.

Authors:  Y H Kim; J H Oh; N H Kim; K M Choi; S J Kim; S H Baik; D S Choi; E S Lee
Journal:  Korean J Intern Med       Date:  2001-06       Impact factor: 2.884

View more
  36 in total

Review 1.  Novel targeted therapies and vaccination strategies for mesothelioma.

Authors:  Mamta Bagia; Anna K Nowak
Journal:  Curr Treat Options Oncol       Date:  2011-06

Review 2.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

Review 3.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

Review 4.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

5.  Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors.

Authors:  Xiaobo Cao; James Littlejohn; Charles Rodarte; Lidong Zhang; Benjamin Martino; Philip Rascoe; Kamran Hamid; Daniel Jupiter; W Roy Smythe
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

6.  Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.

Authors:  Arti Shukla; Jill M Miller; Christopher Cason; Mutlay Sayan; Maximilian B MacPherson; Stacie L Beuschel; Jedd Hillegass; Pamela M Vacek; Harvey I Pass; Brooke T Mossman
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

7.  Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation.

Authors:  Kevin Wilhelmsen; Fengyun Xu; Katherine Farrar; Alphonso Tran; Samira Khakpour; Shirin Sundar; Arun Prakash; Jinhua Wang; Nathanael S Gray; Judith Hellman
Journal:  Sci Signal       Date:  2015-08-25       Impact factor: 8.192

8.  Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.

Authors:  Arti Shukla; Marcus W Bosenberg; Maximilian B MacPherson; Kelly J Butnor; Nicholas H Heintz; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

9.  A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells.

Authors:  Maria E Ramos-Nino; Benjamin Littenberg
Journal:  Mol Cancer Ther       Date:  2008-07-07       Impact factor: 6.261

Review 10.  Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways.

Authors:  Nicholas H Heintz; Yvonne M W Janssen-Heininger; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2010-02       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.